Regenxbio Inc (RGNX) Receives Average Recommendation of “Buy” from Analysts

Shares of Regenxbio Inc (NASDAQ:RGNX) have been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $34.80.

A number of brokerages have recently issued reports on RGNX. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a report on Tuesday, November 28th. ValuEngine cut shares of Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Chardan Capital boosted their price target on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Bank of America boosted their price target on shares of Regenxbio from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, September 21st. Finally, BidaskClub upgraded shares of Regenxbio from a “hold” rating to a “buy” rating in a report on Thursday, December 7th.

Regenxbio (RGNX) opened at $29.95 on Tuesday. Regenxbio has a twelve month low of $16.30 and a twelve month high of $36.10.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.04. The firm had revenue of $1.34 million during the quarter. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. research analysts forecast that Regenxbio will post -2.71 earnings per share for the current year.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $33.25, for a total value of $166,250.00. Following the sale, the chief financial officer now owns 92,283 shares of the company’s stock, valued at $3,068,409.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Curran Simpson sold 21,890 shares of Regenxbio stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $30.04, for a total transaction of $657,575.60. Following the completion of the sale, the senior vice president now directly owns 41,390 shares in the company, valued at approximately $1,243,355.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 99,000 shares of company stock worth $3,130,346. 17.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN raised its position in Regenxbio by 1.1% in the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 175 shares during the period. People s United Financial Inc. raised its position in Regenxbio by 3.4% in the second quarter. People s United Financial Inc. now owns 17,150 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 560 shares during the period. Bank of America Corp DE raised its position in Regenxbio by 1.2% in the first quarter. Bank of America Corp DE now owns 51,380 shares of the biotechnology company’s stock worth $992,000 after acquiring an additional 597 shares during the period. Asymmetry Capital Management L.P. raised its position in Regenxbio by 12.2% in the second quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 1,508 shares during the period. Finally, ProShare Advisors LLC raised its position in Regenxbio by 10.9% in the second quarter. ProShare Advisors LLC now owns 18,252 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 1,790 shares during the period. 68.73% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/19/regenxbio-inc-rgnx-receives-average-recommendation-of-buy-from-analysts.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply